Abliva to issue the Q1 Interim Report by May 31st

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that The Board of Directors of Abliva has decided to publish the company’s Interim Report for the period January-March 2022 by May 31st due to ongoing financing discussions.